HydroGraph Partners with Hawkeye Bio to Power Novel Graphene Biosensor Solution for 尝贰础笔鈩� Lung Cancer Test from Ease Healthcare
HydroGraph (OTCQB: HGRAF) has announced a strategic partnership with Hawkeye Bio and Ease Healthcare to develop 尝贰础笔鈩�, an innovative lung cancer screening test. The test, powered by HydroGraph's ultra-pure graphene, is a non-invasive blood test showing a 99.8% negative predictive value for early lung cancer detection.
The LEAP test targets high-risk populations including smokers, military personnel, and first responders. With current screening compliance at only 2-6% of at-risk individuals, LEAP aims to improve early detection rates among the 15-19.3 million US individuals eligible for annual screening. The technology leverages Hawkeye Bio's patented graphene biosensors, which measure enzymatic activity associated with inflammatory disease.
HydroGraph (OTCQB: HGRAF) ha annunciato una partnership strategica con Hawkeye Bio ed Ease Healthcare per sviluppare 尝贰础笔鈩�, un innovativo test di screening per il cancro polmonare. Il test, basato sul grafene ultra-puro di HydroGraph, 猫 un esame del sangue non invasivo che mostra un valore predittivo negativo del 99,8% per la rilevazione precoce del cancro ai polmoni.
Il test LEAP 猫 rivolto a popolazioni ad alto rischio, tra cui fumatori, personale militare e soccorritori. Con l'attuale aderenza ai programmi di screening che 猫 solo del 2-6% degli individui a rischio, LEAP mira a migliorare i tassi di diagnosi precoce tra i 15-19,3 milioni di persone negli Stati Uniti idonee allo screening annuale. La tecnologia sfrutta i biosensori in grafene brevettati di Hawkeye Bio, che misurano l'attivit脿 enzimatica associata a malattie infiammatorie.
HydroGraph (OTCQB: HGRAF) ha anunciado una alianza estrat茅gica con Hawkeye Bio y Ease Healthcare para desarrollar 尝贰础笔鈩�, una innovadora prueba de cribado del c谩ncer de pulm贸n. La prueba, impulsada por el grafeno ultrapuro de HydroGraph, es un an谩lisis de sangre no invasivo que muestra un valor predictivo negativo del 99,8% para la detecci贸n temprana del c谩ncer de pulm贸n.
La prueba LEAP se dirige a poblaciones de alto riesgo, incluidos fumadores, personal militar y primeros respondedores. Con la tasa actual de cumplimiento de los cribados en solo el 2-6% de las personas en riesgo, LEAP pretende mejorar las tasas de detecci贸n temprana entre los 15-19,3 millones de personas en EE. UU. elegibles para el cribado anual. La tecnolog铆a aprovecha los biosensores de grafeno patentados de Hawkeye Bio, que miden la actividad enzim谩tica asociada con enfermedades inflamatorias.
HydroGraph (OTCQB: HGRAF)電� Hawkeye Bio 氚� Ease Healthcare鞕� 鞝勲灥鞝� 韺岉姼雱堨嫮鞚� 觳搓舶頃橁碃 韽愳晹 靹犽硠 瓴�靷澑 尝贰础笔鈩�毳� 臧滊皽頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. HydroGraph鞚� 齑堨垳靾� 攴鸽灅頃�鞚� 旮半皹鞙茧 頃橂姅 鞚� 瓴�靷姅 牍勳龚鞀奠爜鞚� 順堨暋 瓴�靷, 臁瓣赴 韽愳晹 瓴�於滌棎靹� 99.8%鞚� 鞚岇劚 鞓堨浮臧�鞚� 氤挫瀰雼堧嫟.
LEAP 瓴�靷姅 頋§棸鞛�, 甑办澑 氚� 鞚戧笁 甑“鞖旍洂 霌� 瓿犾渼項橁蛋鞚� 雽�靸侅溂搿� 頃╇媹雼�. 順勳灛 瓿犾渼項� 雽�靸侅瀽鞚� 瓴�歆� 靾橃湪鞚� 雼 2-6%鞐� 攵堦臣頃� 臧�鞖措嵃, LEAP電� 鞐瓣皠 瓴�歆� 雽�靸侅澑 氙戈淡 雮� 1,500毵寏1,930毵�氇呾潣 臁瓣赴 氚滉铂鞙潉 雴掛澊電� 瓴冹潉 氇╉憸搿� 頃╇媹雼�. 鞚� 旮办垹鞚� 鞐检靹� 歆堩櫂瓿� 甏�霠悳 須唽 頇滌劚霃勲ゼ 旄§爼頃橂姅 Hawkeye Bio鞚� 韸鬼棃氚涭潃 攴鸽灅頃� 氚旍澊鞓れ劶靹滊ゼ 頇滌毄頃╇媹雼�.
HydroGraph (OTCQB: HGRAF) a annonc茅 un partenariat strat茅gique avec Hawkeye Bio et Ease Healthcare pour d茅velopper 尝贰础笔鈩�, un test de d茅pistage du cancer du poumon innovant. Le test, propuls茅 par le graph猫ne ultra-pur de HydroGraph, est un test sanguin non invasif affichant une valeur pr茅dictive n茅gative de 99,8% pour la d茅tection pr茅coce du cancer du poumon.
Le test LEAP cible les populations 脿 haut risque, notamment les fumeurs, le personnel militaire et les premiers intervenants. Alors que l'adh茅sion actuelle au d茅pistage n'est que de 2-6% des personnes 脿 risque, LEAP vise 脿 am茅liorer les taux de d茅tection pr茅coce parmi les 15鈥�19,3 millions de personnes aux 脡tats-Unis 茅ligibles au d茅pistage annuel. La technologie s'appuie sur les biosenseurs en graph猫ne brevet茅s de Hawkeye Bio, qui mesurent l'activit茅 enzymatique associ茅e aux maladies inflammatoires.
HydroGraph (OTCQB: HGRAF) hat eine strategische Partnerschaft mit Hawkeye Bio und Ease Healthcare angek眉ndigt, um 尝贰础笔鈩� zu entwickeln, einen innovativen Screening-Test auf Lungenkrebs. Der Test, angetrieben von HydroGraphs ultrareinem Graphen, ist ein nicht-invasiver Bluttest, der einen negativen pr盲diktiven Wert von 99,8% f眉r die Fr眉herkennung von Lungenkrebs aufweist.
Der LEAP-Test richtet sich an Hochrisikogruppen wie Raucher, Milit盲rangeh枚rige und Ersthelfer. Da die derzeitige Screening-Compliance nur bei 2-6% der gef盲hrdeten Personen liegt, zielt LEAP darauf ab, die Fr眉herkennungsraten unter den 15鈥�19,3 Millionen in den USA j盲hrlich screeningelegiblen Personen zu verbessern. Die Technologie nutzt die patentierten Graphen-Biosensoren von Hawkeye Bio, die enzymatische Aktivit盲ten messen, die mit entz眉ndlichen Erkrankungen in Verbindung stehen.
- Test demonstrates exceptional 99.8% negative predictive value for lung cancer detection
- Technology addresses a large market with 15-19.3 million eligible screening candidates in the US
- Future expansion potential to detect 14 different cancers, Alzheimer's, and Multiple Sclerosis
- Global patent protection across major markets including US, UK, EU, Japan, Korea, Hong Kong, and Taiwan
- Current lung cancer screening compliance remains very low at 2-6% of at-risk individuals
- Product still needs to establish market adoption and penetration
New Commercial Partnership Demonstrates Medical Potential of HydroGraph Ultra-Pure Graphene for Medical Testing Applications
VANCOUVER, British Columbia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- HydroGraph Inc. (CSE: HG) (OTCQB: HGRAF) (鈥淗ydroGraph鈥�), a leading producer of ultra-pure graphene, today announced its role in a new lung cancer screening product underpinning a collaboration between Hawkeye Bio (Torrance, California) and Ease Healthcare (Pasadena, California). Under a new commercialization agreement, Ease Healthcare will market the LEAP (Lung Enzyme Activity Profile) early detection test that incorporates HydroGraph鈥檚 patented fractal graphene.
LEAP is a non-invasive, radiation-free, and highly sensitive blood test designed to detect early signs of lung cancer, even in asymptomatic patients, and across all subtypes. Initially targeting high-risk populations including older smokers, military personnel, firefighters, and first responders, the test has demonstrated a
HydroGraph鈥檚 explosion synthesis technology produces ultra-pure graphene that forms the foundation of Hawkeye Bio鈥檚 patented biosensor which measures enzymatic activity associated with inflammatory disease鈥攁 key biomarker in early-stage cancer detection.
鈥淭his partnership underscores the medical potential of high-purity graphene,鈥� said Kjirstin Breure, President and CEO of HydroGraph. 鈥淥ur ability to deliver graphene at scale supports groundbreaking diagnostics like Hawkeye鈥檚 biosensors and Ease鈥檚 LEAP test, ultimately saving lives through earlier detection and intervention.鈥�
Lung cancer is the leading cause of cancer deaths, with the American Cancer Society estimating nearly in 2025. Screening compliance remains low, with and undergoing recommended low-dose CT scans annually, despite evidence that early detection is associated with significantly better .
鈥淚n addition to tobacco use, can significantly increase one鈥檚 risk of getting lung cancer,鈥� said Andr茅 de Fusco, CEO and co-founder of Hawkeye Bio. 鈥淚mproved compliance with lung cancer screening guidelines may lead to earlier detection and improve radiotherapy and surgical outcomes. Our nano-scale graphene biosensors allow Ease Healthcare to bring LEAP testing to primary care physicians as a cost-effective diagnostic solution they can use in routine medical visits.鈥�
Hawkeye Bio is the first company to manufacture nanoscale graphene biosensors for clinical cancer detection and holds global patents across the U.S., UK, EU, Japan, Korea, Hong Kong, and Taiwan. The company aims to substantially reduce lung cancer mortality by offering a patient-safe, affordable solution to achieve population-scale lung cancer screening compliance for at-risk individuals.
Presently . Hawkeye Bio projects this eligible population to increase as national screening guidelines evolve to incorporate additional risk factors beyond smoking history. Future LEAP platforms will plan to address 14 cancers, neurodegenerative disease (Alzheimer鈥檚) and inflammatory conditions such as Multiple Sclerosis.
About Hawkeye Bio
Hawkeye Bio is a clinical-stage biotechnology company developing low-cost diagnostic tests for early detection of cancer, neurodegenerative, and inflammatory diseases. Using a patented biosensor technology, the company measures misregulated proteolytic enzymes linked to conditions such as cancer, arthritis, and cardiovascular disease. Its first program, the LEAP test for early lung cancer detection, has shown a
About HydroGraph
HydroGraph is a leading producer of pristine graphene using an 鈥渆xplosion synthesis鈥� process, which allows for exceptional purity, low energy use, and identical batches. The quality, performance, and consistency of HydroGraph鈥檚 graphene meets the Graphene Council鈥檚 Verified Graphene Producer庐 standards, which very few companies worldwide achieve. For more information or to learn about the HydroGraph story, visit:聽. For company updates, please follow HydroGraph on LinkedIn and X.
Trademarks: HydroGraph鈩� and Fractal Graphene鈩�
Forward-Looking Statements
This release contains certain 鈥渇orward-looking statements鈥� and certain 鈥渇orward-looking information鈥� as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as 鈥渕ay鈥�, 鈥渨ill鈥�, 鈥渆xpect鈥�, 鈥渋ntend鈥�, 鈥渆stimate鈥�, 鈥渦pon鈥�, 鈥渁nticipate鈥�, 鈥渂elieve鈥�, 鈥渃ontinue鈥�, 鈥減lans鈥� or similar terminology.聽
Forward-looking statements and information include, but are not limited to: statements in respect of the Private Placement, the use of the net proceeds from the Private Placement,聽the timing and ability of the Company to close the Private Placement, if at all, the gross proceeds of the Private Placement, the timing and ability of the Company to obtain all necessary regulatory approvals, if at all, and the terms and jurisdictions of the Private Placement; the statements in regards to existing and future products of the Company; the Company鈥檚 future personnel appointments; the Company鈥檚 plans and strategies.聽
Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable, and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic, and competitive uncertainties and contingencies. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of HydroGraph to control or predict, that may cause HydroGraph鈥檚 actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein, including but not limited to: HydroGraph鈥檚 ability to implement its business strategies; risks associated with general economic conditions; adverse industry events; stakeholder engagement; marketing and transportation costs; loss of markets; volatility of commodity prices; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; industry and government regulation; changes in legislation, income tax and regulatory matters; competition; currency and interest rate fluctuations; and other risks. HydroGraph does not undertake any obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management鈥檚 best judgment based on information currently available.聽
No forward-looking statement can be guaranteed, and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements.聽
FOR FURTHER INFORMATION PLEASE CONTACT:
Kjirstin Breure 鈥� President & CEO, HydroGraph
480-267-2556
Media Contact
Len Fernandes
Firecracker PR for HydroGraph
818-317-4687
Photos accompanying this announcement are available at:
FAQ
What is the LEAP lung cancer test by HydroGraph (HGRAF) and how does it work?
Who is the target market for HydroGraph's LEAP cancer screening test?
What is the current lung cancer screening compliance rate in the US?
What are the future applications planned for HydroGraph's LEAP technology?
What patents does Hawkeye Bio hold for the graphene biosensor technology?
